PE52996A1 - FRAGMENTO mAb MONOVALENTE (fab) DE mAb QUE TIENE LA CAPACIDAD DE REDUCIR LA SENSIBILIDAD DE LA EXPRESION DEL HLA-DR EN CELULAS PRESENTADORAS DEL ANTIGENO - Google Patents

FRAGMENTO mAb MONOVALENTE (fab) DE mAb QUE TIENE LA CAPACIDAD DE REDUCIR LA SENSIBILIDAD DE LA EXPRESION DEL HLA-DR EN CELULAS PRESENTADORAS DEL ANTIGENO

Info

Publication number
PE52996A1
PE52996A1 PE1995286338A PE28633895A PE52996A1 PE 52996 A1 PE52996 A1 PE 52996A1 PE 1995286338 A PE1995286338 A PE 1995286338A PE 28633895 A PE28633895 A PE 28633895A PE 52996 A1 PE52996 A1 PE 52996A1
Authority
PE
Peru
Prior art keywords
fab
hla
mab
monoclonal antibody
presenting cells
Prior art date
Application number
PE1995286338A
Other languages
English (en)
Spanish (es)
Inventor
Zoltan Nagy
Damir Vidovic
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE52996A1 publication Critical patent/PE52996A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PE1995286338A 1994-12-07 1995-12-04 FRAGMENTO mAb MONOVALENTE (fab) DE mAb QUE TIENE LA CAPACIDAD DE REDUCIR LA SENSIBILIDAD DE LA EXPRESION DEL HLA-DR EN CELULAS PRESENTADORAS DEL ANTIGENO PE52996A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35091594A 1994-12-07 1994-12-07

Publications (1)

Publication Number Publication Date
PE52996A1 true PE52996A1 (es) 1996-12-12

Family

ID=23378740

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1995286338A PE52996A1 (es) 1994-12-07 1995-12-04 FRAGMENTO mAb MONOVALENTE (fab) DE mAb QUE TIENE LA CAPACIDAD DE REDUCIR LA SENSIBILIDAD DE LA EXPRESION DEL HLA-DR EN CELULAS PRESENTADORAS DEL ANTIGENO

Country Status (19)

Country Link
EP (1) EP0787151A1 (pt)
JP (1) JP2001506122A (pt)
CN (1) CN1168679A (pt)
AR (1) AR002005A1 (pt)
AU (1) AU4256096A (pt)
BR (1) BR9509902A (pt)
CA (1) CA2206471A1 (pt)
CO (1) CO4480041A1 (pt)
CZ (1) CZ172497A3 (pt)
FI (1) FI972430A7 (pt)
HU (1) HUT77342A (pt)
IL (1) IL116228A0 (pt)
MA (1) MA23739A1 (pt)
NO (1) NO972522L (pt)
PE (1) PE52996A1 (pt)
PL (1) PL320610A1 (pt)
TR (1) TR199501542A2 (pt)
WO (1) WO1996017874A1 (pt)
ZA (1) ZA9510195B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0893507A1 (en) * 1997-07-25 1999-01-27 Institut Gustave Roussy Use of MHC class II ligands (CD4 and LAG-3) as adjuvant for vaccination and of LAG-3 in cancer treatment
AU5588099A (en) 1998-08-28 2000-03-21 Dendreon Corporation Selective apoptosis of neoplastic cells by an hla-dr specific monoclonal antibody
EP1156062A1 (en) * 2000-05-12 2001-11-21 GPC Biotech AG Immunomodulatory human MHC class II antigen-binding peptides/proteins
ATE365749T1 (de) * 2000-05-12 2007-07-15 Gpc Biotech Ag Humane peptide/proteine, die das töten von zellen,einschliesslich lymphoide tumorzellen, herbeiführen oder bewirken
US7521047B2 (en) 2000-05-12 2009-04-21 Gpc Biotech Ag Human polypeptides causing or leading to the killing of cells including lymphoid tumor cells
US20030086929A1 (en) 2001-10-11 2003-05-08 Tso J. Yun Treatment of prostate cancer by inhibitors of ATP synthase
EP1369431A4 (en) 2001-10-15 2005-01-12 Kirin Brewery ANTI-HLA-DR ANTIBODIES
EP1768662A2 (en) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
EP2552483A4 (en) * 2010-04-01 2013-09-25 Immunomedics Inc USE OF ANTIBODIES TO REDUCE THE NUMBER OF CELLS CONTAINING ANTIGENS AND DENDRITIC CELLS
KR102647825B1 (ko) * 2021-07-22 2024-03-14 서울대학교산학협력단 항-hla-dp 단클론 항체 및 이의 용도

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0068790B1 (en) * 1981-06-25 1986-02-26 The Board Of Trustees Of The Leland Stanford Junior University Allele specific immunotherapeutic method and dosage form
JPH05502586A (ja) * 1989-12-27 1993-05-13 セントカー・インコーポレーテツド Ｃｄ４受容体に対するキメラ免疫グロブリン
NZ243706A (en) * 1991-07-25 1994-08-26 Idec Pharma Corp Recombinant monkey antibodies, pharmaceutical compositions

Also Published As

Publication number Publication date
NO972522L (no) 1997-08-06
IL116228A0 (en) 1996-03-31
MX9704225A (es) 1997-09-30
TR199501542A2 (tr) 1996-07-21
BR9509902A (pt) 1997-10-21
FI972430L (fi) 1997-06-06
PL320610A1 (en) 1997-10-13
AR002005A1 (es) 1998-01-07
ZA9510195B (en) 1996-06-07
EP0787151A1 (en) 1997-08-06
CO4480041A1 (es) 1997-07-09
CZ172497A3 (en) 1997-10-15
MA23739A1 (fr) 1996-07-01
WO1996017874A1 (en) 1996-06-13
FI972430A0 (fi) 1997-06-06
FI972430A7 (fi) 1997-06-06
NO972522D0 (no) 1997-06-03
AU4256096A (en) 1996-06-26
CA2206471A1 (en) 1996-06-13
CN1168679A (zh) 1997-12-24
HUT77342A (hu) 1998-03-30
JP2001506122A (ja) 2001-05-15

Similar Documents

Publication Publication Date Title
US20210011021A1 (en) Glycan-Interacting Compounds and Methods of Use
CN110913903B (zh) 聚糖相互作用化合物和使用方法
US8119135B2 (en) Antibodies which bind to epitopes of glycoprotein VI
Capra et al. Light chain sequences of human IgM cold agglutinins
AR021296A1 (es) Un anticuerpo humanizado especifico para 4-1bb humano y composiciones farmaceuticas que lo comprenden
US20220396627A1 (en) Anti-siglec-9 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof
JP2025129213A (ja) 骨髄細胞炎症性表現型を調節するための抗ｐｓｇｌ－１組成物及び方法、ならびにその使用
PE20061323A1 (es) Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
Hansen et al. A mouse aminopeptidase N is a marker for antigen‐presenting cells and appears to be co‐expressed with major histocompatibility complex class II molecules
Baniel et al. Intratumoral injection reduces toxicity and antibody-mediated neutralization of immunocytokine in a mouse melanoma model
US20220251233A1 (en) Anti-cd53 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof
KR20230017778A (ko) 골수성 세포 염증성 표현형을 조절하기 위한 항-vsig4 조성물 및 방법, 그리고 이의 용도
ATE248189T1 (de) Antikörper gegen vasp (vasodilator-stimulated phosphoprotein), hybridomzellen für deren gewinnung, und deren verwendung
Sundsmo et al. Human monocyte spreading induced by factor Bb of the alternative pathway of complement activation. A possible role for C5 in monocyte spreading.
EP1476467B9 (fr) Immunoglobuline igg3 marqueur de protection contre les maladies virales infectieuses et ses utilisations
CO4480041A1 (es) Fragmentos de anticuerpos monoclonales que tienen actividad inmunosupresora
Zhang et al. Targeting of functional antibody-decay-accelerating factor fusion proteins to a cell surface
Roos et al. Both IgG and IgM anti‐pig antibodies induce complement activation and cytotoxicity
CN101300021A (zh) 抗体及其用途
ATE406178T1 (de) Verhinderung von immunreaktivität durch verarmung oder inhibition von antigen-präsentierenden zellen
ES2082132T3 (es) Composicion que contiene al menos dos anticuerpos distintos o fragmentos de ellos.
Yano et al. Natural antibodies against the immunoglobulin F (ab′) 2 fragment cause elimination of antigens recognized by the F (ab′) 2 from the circulation
WO2006004950A3 (en) Humanized monoclonal antibody 31.1 as an anticancer agent
Altindal et al. Desensitization in HLA-incompatible kidney transplant recipients: current strategies and emerging perspectives
RU2782950C2 (ru) Подкожное введение анти-cd38 антител

Legal Events

Date Code Title Description
FD Application declared void or lapsed